Cannabis Extracts for MS Spasticity: What the Latest Trials Showed in 2004 | Research

The takeaway

A critical review noted that oral THC failed to objectively reduce MS spasticity in recent trials, while sublingual THC:CBD extracts showed more promise but needed further validation.

Read this if you have MS and want to understand why the specific formulation and delivery method of cannabis medicine matters.

Oral THC failed objectively; sublingual THC:CBD showed more promise for MS spasticity

What the researchers found

The review contrasted two approaches to cannabis-based MS treatment. Orally administered THC had failed to demonstrate objective spasticity reduction in placebo-controlled trials. However, sublingually administered cannabis extracts containing approximately equal concentrations of THC and CBD were claimed to produce statistically and clinically significant spasticity reduction, though this claim needed further validation.

The author noted that preclinical evidence continued to support the involvement of the endocannabinoid system in regulating spasticity and pain, maintaining the theoretical basis for cannabinoid treatment even as clinical results were mixed.

Why it matters

This review highlighted an important distinction between formulations: oral THC alone versus sublingual THC:CBD. The suggestion that the combination formulation and delivery method mattered was clinically significant and aligned with the development of Sativex (which is sublingual THC:CBD).

The numbers in context

No specific quantitative data were presented in the abstract.

How the study worked

This was a critical review evaluating the most recent clinical trial evidence for cannabis extracts in MS pain and spasticity, comparing oral THC with sublingual THC:CBD formulations.

What this study cannot tell us

The review was published before all major trial results were available. The critical assessment reflected one author's interpretation of limited data. The claim that sublingual THC:CBD was superior to oral THC was not yet thoroughly validated.

How to read the evidence

This is a critical review comparing clinical trial results for different formulations, providing moderate-level evidence through expert analysis.

When this study was published

Published in 2004. Sativex (sublingual THC:CBD) was subsequently approved, validating the direction identified here.

The bigger picture

The distinction between oral THC and sublingual THC:CBD identified here proved important. Sativex (sublingual THC:CBD) was subsequently approved for MS spasticity, while oral THC alone was not. The review correctly identified the more promising approach.

Questions still open

Is the advantage of sublingual THC:CBD due to the route of administration, the addition of CBD, or both? Has subsequent evidence validated the superiority of sublingual delivery?

Common questions

Why do THC pills not work as well as THC:CBD spray for MS?

This review suggested that oral THC alone failed to objectively reduce spasticity, while sublingual THC:CBD extracts showed better results. This may be due to CBD enhancing THC's therapeutic effects, the faster absorption of sublingual delivery, or both.

What is the difference between oral and sublingual delivery?

Oral delivery (swallowed) requires the drug to pass through the digestive system and liver, altering its effects. Sublingual delivery (under the tongue) allows faster absorption directly into the bloodstream, potentially providing quicker onset and different metabolite profiles.

Read the original research

Medicinal cannabis extracts for the treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000), 5(7), 727-30

View on PubMed ↗

Citation

Smith, Paul F. (2004). Medicinal cannabis extracts for the treatment of multiple sclerosis.. Current opinion in investigational drugs (London, England : 2000), 5(7), 727-30.